Page last updated: 2024-08-21

paeonol and Cardiotoxicity

paeonol has been researched along with Cardiotoxicity in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
De, D; Ding, M; Du, Y; Fu, F; Li, M; Li, Z; Shi, R1
Cao, H; Guo, R; Jiang, W; Kong, F; Li, J; Sun, D; Wu, J; Xue, X; Zhang, B1

Other Studies

2 other study(ies) available for paeonol and Cardiotoxicity

ArticleYear
Paeonol protects against doxorubicin-induced cardiotoxicity by promoting Mfn2-mediated mitochondrial fusion through activating the PKCĪµ-Stat3 pathway.
    Journal of advanced research, 2023, Volume: 47

    Topics: Animals; Cardiotoxicity; Doxorubicin; Hydrolases; Mitochondrial Dynamics; Molecular Docking Simulation; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley

2023
Enhanced antitumor activity and attenuated cardiotoxicity of Epirubicin combined with Paeonol against breast cancer.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:9

    Topics: Acetophenones; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Breast Neoplasms; Cardiotoxicity; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Epirubicin; Female; Humans; Immunohistochemistry; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice, Inbred BALB C; Microscopy, Fluorescence; Mitogen-Activated Protein Kinases; Tumor Burden

2016